Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2
- PMID: 16103083
- DOI: 10.1158/0008-5472.CAN-05-1403
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2
Abstract
Half of patients treated for locally advanced bladder cancer relapse with often fatal metastatic disease to the lung. We have recently shown that reduced expression of the GDP dissociation inhibitor, RhoGDI2, is associated with decreased survival of patients with advanced bladder cancer. However, the effectors by which RhoGDI2 affects metastasis are unknown. Here we use DNA microarrays to identify genes suppressed by RhoGDI2 reconstitution in lung metastatic bladder cancer cell lines. We identify such RNAs and focus only on those that also increase with tumor stage in human bladder cancer samples to discover only clinically relevant targets of RhoGDI2. Levels of endothelin-1 (ET-1), a potent vasoconstrictor, were affected by both RhoGDI2 reconstitution and tumor stage. To test the hypothesis that the endothelin axis is important in lung metastasis, lung metastatic bladder carcinoma cells were injected in mice treated with the endothelin receptor-specific antagonist, atrasentan, thereby blocking engagement of the up-regulated ET-1 ligand with its cognate receptor. Endothelin antagonism resulted in a dramatic reduction of lung metastases, similar to the effect of reexpressing RhoGDI2 in these metastatic cells. Taken together, these experiments show a novel approach of identifying therapeutic targets downstream of metastasis suppressor genes. The data also suggest that blockade of the ET-1 axis may prevent lung metastasis, a new therapeutic concept that warrants clinical evaluation.
Similar articles
-
RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation.Urol Oncol. 2007 Sep-Oct;25(5):401-6. doi: 10.1016/j.urolonc.2007.05.006. Urol Oncol. 2007. PMID: 17826660 Review.
-
Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.Oncogene. 2007 Feb 1;26(5):765-73. doi: 10.1038/sj.onc.1209835. Epub 2006 Jul 31. Oncogene. 2007. PMID: 16878152
-
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.Cancer Res. 2002 Nov 15;62(22):6418-23. Cancer Res. 2002. PMID: 12438227
-
Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.Clin Cancer Res. 2004 Jun 1;10(11):3800-6. doi: 10.1158/1078-0432.CCR-03-0653. Clin Cancer Res. 2004. PMID: 15173088
-
RhoGDI2 as a therapeutic target in cancer.Expert Opin Ther Targets. 2010 Jan;14(1):67-75. doi: 10.1517/14728220903449251. Expert Opin Ther Targets. 2010. PMID: 20001211 Review.
Cited by
-
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.Am J Pathol. 2009 Feb;174(2):371-9. doi: 10.2353/ajpath.2009.080538. Epub 2009 Jan 15. Am J Pathol. 2009. PMID: 19147813 Free PMC article.
-
Metastasis suppressors: functional pathways.Lab Invest. 2018 Feb;98(2):198-210. doi: 10.1038/labinvest.2017.104. Epub 2017 Oct 2. Lab Invest. 2018. PMID: 28967874 Free PMC article. Review.
-
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application.Clin Cancer Res. 2006 Jul 1;12(13):3882-9. doi: 10.1158/1078-0432.CCR-06-1014. Clin Cancer Res. 2006. PMID: 16818682 Free PMC article. Review.
-
Translational approaches using metastasis suppressor genes.J Bioenerg Biomembr. 2006 Aug;38(3-4):151-61. doi: 10.1007/s10863-006-9039-9. J Bioenerg Biomembr. 2006. PMID: 16944301 Review.
-
The role of metastasis suppressor genes in metastatic dormancy.APMIS. 2008 Jul-Aug;116(7-8):586-601. doi: 10.1111/j.1600-0463.2008.01213.x. APMIS. 2008. PMID: 18834404 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous